Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial - Wikidata - wikimedia - TriplyDB

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

http://www.wikidata.org/entity/Q36351758

about

Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events Addition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthma Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review Approach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), Iran Revisiting early intervention in adult asthma Antileukotriene agents for the treatment of lung disease Allergic rhinitis: evidence for impact on asthma Allergic rhinitis and asthma: inflammation in a one-airway condition.Role of Leukotrienes and Leukotriene Modifiers in Asthma.Comparing the efficacy and influence on the quality of life of three classes of drugs used in bronchial asthma - a prospective study.Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.Risk factors for montelukast treatment failure in step-down therapy for controlled asthma Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues.Scientific respiratory symposium, paris june 2010 Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.A review of montelukast in the treatment of asthma and allergic rhinitis.Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly.Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study Recent developments in asthma management Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial).Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial)Montelukast in asthma: a review of its efficacy and place in therapy.The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1 Stratified approaches to the treatment of asthma.Effects of add-on montelukast on airway hyperresponsiveness in patients with well-controlled asthma - a pilot study Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.Effect of fluticasone 250 microg/salmeterol 50 microg and montelukast on exhaled nitric oxide in asthmatic patients.Evaluating combination therapies for asthma: pros, cons, and comparative benefits.Pharmacotherapy of asthma: regular treatment or on demand?Leukotriene modifiers in the treatment of asthma in children.Montelukast in the treatment of asthma as a systemic disease.Effects of asthma treatment: the present and future.

P2860

Q24197585-EA1DFE04-77A9-4215-BFEC-C5E5BA23A8E5 Q24197682-F678BE30-9CB6-4C6A-AAF1-F72F363835BA Q24199079-1F1BBD6A-C030-4922-9EE2-071A875F5311 Q24200999-EA344943-7B21-4DE6-9C62-37A7B5A3B980 Q24234499-1C87403E-37CA-4485-8CE0-38F57432461B Q24235303-E574DFCF-2371-443B-8D03-6C1CE9EB420F Q24240464-7D785704-B7B3-4E67-83EF-C8B2001FBA22 Q24241740-33979F63-6DE4-43BE-92CC-5012A493A9F5 Q24244152-61412E3E-20AA-4473-A8A8-58789881B724 Q24245719-C7A8FDF1-8FDC-4B4F-96A0-E6952146B547 Q24794527-63819C1B-1103-4442-A135-D8D574DFBB7D Q26777154-695DA828-7400-484E-9F69-1678C0E4C056 Q28071831-677A8306-75E9-4B1A-8A6A-1729CFC706F3 Q28293842-9A93ADE7-BBA5-4031-9B87-22EDDA0B157D Q33265228-C6389CA1-1748-42E3-BA7A-B3DEF2486739 Q33265229-228ABFF4-0E11-4DC7-BD17-845A62D8F1C1 Q33664150-8227D786-0B2A-4D34-8E3C-F98639698959 Q34479734-645D1AAE-CD35-4D7A-97A9-0D864F3420D5 Q34693644-28D295B9-186A-414B-96F5-CB494982E7C3 Q34778001-5FCF3607-A1D0-41BA-A2D5-303EDEA867AD Q35113606-D213A84B-6877-4BF3-AC98-060FD9AAC35A Q35117833-B2667DCA-8BAF-48D3-95C6-92AC243895EE Q35523534-5231EE25-B577-4DDA-9D87-FDE0CB5E5C2B Q35688199-B99DFC34-FC34-4027-9639-99AC57BAF383 Q35765263-E14A11DC-9BDD-463D-98FC-D5A9E0991F47 Q35798055-4F08585D-1CEE-47D5-9C48-1D7ECF5E6C80 Q36067978-950FCC46-F502-4377-988B-4C137ECD2B1A Q36364530-581938B3-E179-48ED-8650-833D657E0B3D Q36364534-4726E743-5130-40A1-A972-79767E663AF3 Q36443703-47D75073-5CCE-4A84-9C12-7A29F92FBAF7 Q36929333-A620CD35-E2ED-4ECF-A8AF-7533C9DF0FE3 Q37064755-9E3452C1-41FE-414D-B5BA-07DB013C402A Q37077214-C624E0F9-153B-4988-A798-ABC1AE3039BB Q37137128-C828C4A4-2AA1-44C8-839C-68DA4C9994C0 Q37181742-61EE3EB9-CE48-42E4-97F6-F4326CEC1FB4 Q37362610-41D2C689-14D0-46A2-987F-294DC2BBD281 Q37578103-225F8478-4045-4815-BBE4-8D61992CC1C3 Q37613312-0F7D537D-76A5-4873-8BB5-83C299453DD9 Q37754612-087102CD-615F-47BF-8AE9-187C9A5F7380 Q37755242-F144EE77-6064-40D3-AEF5-AE7272BF825D

P2860

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

http://www.wikidata.org/entity/Q36351758

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Montelukast and fluticasone co ...... randomised, comparative trial

@ast

Montelukast and fluticasone co ...... randomised, comparative trial

@en

type

label

Montelukast and fluticasone co ...... randomised, comparative trial

@ast

Montelukast and fluticasone co ...... randomised, comparative trial

@en

prefLabel

Montelukast and fluticasone co ...... randomised, comparative trial

@ast

Montelukast and fluticasone co ...... randomised, comparative trial

@en

P1433

Q36351758-7F209181-8048-4C3F-9E60-582D1559813A

P1476

Q36351758-EFFABD89-FC99-48B6-BB3A-D5B899CD7193

P2093

Q36351758-2CA8B26C-6086-4B89-B4AC-85D200A1343E

Q36351758-3EEB874D-55CC-4CEA-ADA2-620461150855

Q36351758-47DC0B83-20B2-4AC5-B205-58DED78B3A92

Q36351758-4F2EB57E-FF69-4DFF-955D-CC5305041484

Q36351758-60DF85D7-1855-4723-86C3-F4998F70436A

Q36351758-89B5956F-F3C5-484A-A2BD-870EE594F1F4

Q36351758-8C6EE5E7-9EC8-4446-A0F7-C56D3EBAEEE9

Q36351758-9DEB1AD8-4FB8-496C-A254-50ED99097CA2

P2860

Q36351758-182E6FF8-64B3-4726-AEAA-CE5582CB86DC

Q36351758-2DB29A22-252B-4296-81B6-F5B386009244

Q36351758-4492FECA-8CEC-41A4-B3D6-7FBC7766EAEF

Q36351758-4D8F0E7B-2B3C-440B-B10A-F104DC20A71F

Q36351758-56CB34D5-9487-4827-A89F-78A982C75F7B

Q36351758-571A03DA-C706-4A00-9408-296391607132

Q36351758-6033F716-16BF-4A7E-B2A3-430ACF423CD9

Q36351758-6ED7AED9-78E9-43E4-8BB6-DB15A6E82BC8

Q36351758-7B5B3F4D-9079-496C-9C07-C9C38AD42C89

Q36351758-8B10A66B-0065-47F3-ADF7-A30401D93964

P304

Q36351758-171DE100-2E57-4AE5-9087-7C78BC1F9739

P31

Q36351758-B22EA822-E901-4F7C-8A02-7D0B5FC7BF64

P356

Q36351758-9C604D44-B27D-4B3B-A7F9-22468C9748E7

P407

Q36351758-4D228C24-0F44-4F3F-B4C9-1A95B70FCACE

P433

Q36351758-8ED52B29-C35C-4F65-AB88-DE7EBEE64C4A

P478

Q36351758-5A0BF78A-D94A-45CD-97AB-5C7B533334F4

P50

Q36351758-10923C16-9310-47F2-BFB7-3814DC7084C5

Q36351758-442DD404-0315-4CD6-B455-C7EEA5E13DD3

Q36351758-482B997F-D387-4FE7-A0B6-4B69C266E795

Q36351758-8F78D9EB-C6FC-4C50-9DE8-74B76B48F95B

P577

Q36351758-8DA74A6C-1CAD-4EF1-AA3B-61CD79229C55

P5875

Q36351758-F37A8403-2B62-49AE-A1CC-BB8B860BC3BB

P698

Q36351758-A95A274C-4FDB-4BAC-A20C-E9F80AB44D4B

P921

Q36351758-0D35CC40-0A39-46F3-845D-85EC7B87AFF9

P932

Q36351758-5C2747A2-263B-433E-B6D2-C5AA1723805D

P356

BMJ.327.7420.891

P1433

P1476

Montelukast and fluticasone co ...... randomised, comparative trial

@en

P2093

Andrew P Greening

http://www.w3.org/2001/XMLSchema#string

Cesar Picado

http://www.w3.org/2001/XMLSchema#string

Jean Bousquet

http://www.w3.org/2001/XMLSchema#string

Jonathan A Leff

http://www.w3.org/2001/XMLSchema#string

Joris Menten

http://www.w3.org/2001/XMLSchema#string

Leonardo M Fabbri

http://www.w3.org/2001/XMLSchema#string

Peter G Polos

http://www.w3.org/2001/XMLSchema#string

S Balachandra Dass

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods.

Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.

Montelukast: a review of its therapeutic potential in persistent asthma.

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

Allergic inflammation and airway smooth muscle function.

Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma.

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

Efficacy of inhaled corticosteroids in asthma.

P304

891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.327.7420.891

http://www.w3.org/2001/XMLSchema#string

P407

P433

7420

http://www.w3.org/2001/XMLSchema#string

P478

327

http://www.w3.org/2001/XMLSchema#string

P50

Stephen T. Holgate

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9046617

http://www.w3.org/2001/XMLSchema#string

P698

14563743

http://www.w3.org/2001/XMLSchema#string

P921

P932

218809

http://www.w3.org/2001/XMLSchema#string